Abstract
CRISPR Cas9 nucleases have revolutionized the field of gene editing and high-throughput lentiviral screens continue to hold ever-increasing promise for both basic research and development of future therapies to benefit human health. Even with such powerful technologies at hand, researchers new to the field may find screening of multiple targets to be challenging and time-consuming. This webinar discusses the Evotec partnership between us and the screening services for drug discovery.
What Will You Learn?
- Introduction to CRISPR pooled and arrayed screening concepts
- Target identification with Lentiviral CRISPR KO libraries for the discovery of disease relevant genes
- Evotec partnership highlights phenotypic screening capabilities across therapeutic areas
Who Should Watch?
Post-Docs, Managers, Scientists, Clinicians, Team Leads, Directors and Executives from Pharma, Biotech, Academia, Contract Research Labs and Technology Providers involved in Target Discovery, Disease Modeling, Functional Screening, High-Throughput Screening, Assay Development and Translational Research.
Speakers
Shawn Shafer, Ph.D.
Advanced Genomics Market Segment Manager
Merck
Dr. Shafer leads a team responsible for product development of Merck’s RNAi and genome editing portfolios. He orchestrated the creation of Merck CRISPR collection of reagents.
Hauke Cornils, PhD
Merck
Research Scientist In Vitro Pharmacology
Hauke Cornils is leading the CRISPR technology platform at Evotec. He has more than 9 years of academic and industrial research experience, including a PhD at the Friedrich-Miescher Institute for Biomedical Research in Basel, Switzerland and a Post-Doc at the Dana-Farber Cancer Institute in Boston, US. His interests focus on understanding signal transduction in health and disease using phenotypic and genomic approaches
Research and disease areas
- Pharmacology and drug discovery research
Duration:50min
語言:English
會話 1:提出 May 31, 2021
若要繼續閱讀，請登入或建立帳戶。
還沒有帳戶？